Prevalence of HIV Antiretroviral Drug Resistance and Its Impacts on HIV-1 Virological Failures in Jiangsu, China: A Cross-Sectional Study
Table 1
Demographic characteristics of HIV-1 treated patients with virological failure on ART and univariate analyses for correlates of drug resistance.
Variables
Virologic failure
Drug resistance % ()
value
value
()
%
Age (years)
0.050
0.975
<30
38
19.4
50 (19)
30–50
121
61.7
52.1 (63)
>50
37
18.9
51.4 (19)
Gender
3.424
0.064
Male
159
81.1
54.7 (87)
Female
37
18.9
37.8 (14)
Marital status
0.161
0.923
Single
52
26.5
53.8 (28)
Married
110
56.1
50.9 (56)
Other
34
17.3
50.0 (17)
Routes of infection
4.876
0.300
Blood
11
5.6
63.6 (7)
IDU
6
3.1
66.7 (4)
MSM
68
34.7
57.4 (39)
Hetro
96
49.0
43.8 (42)
Other
15
7.7
60.0 (9)
WHO clinical stages
10.442
0.015
I
101
51.5
40.6 (41)
II
50
25.5
60.0 (30)
III
28
14.3
67.9 (19)
IV
17
8.7
64.7 (11)
Treatment duration
18.376
0.000
<1
16
8.2
6.2 (1)
1-2
120
61.2
52.5 (63)
2-3
39
19.9
53.8 (21)
>3
21
10.7
76.2 (16)
Side effect
3.594
0.058
Yes
13
6.6
76.9 (10)
No
183
93.4
49.7 (91)
SMZ taken
4.280
0.039
Yes
11
5.6
81.8 (9)
No
185
94.4
49.7 (92)
Treatment regimen
1.909
0.592
AZT/D4T + 3TC + NVP/EFV
176
89.8
51.1 (90)
TDF + 3TC + NVP/EFV
14
7.1
50.0 (7)
AZT + 3TC + LPV/r
4
2.0
50.0 (2)
AZT + TDF + LPV/r
2
1.0
100 (2)
IDU: intravenous drug use; MSM: men who have sex with men; hetro: heterosexual; SMZ: compound sulfamethoxazole; AZT: zidovudine; TDF: tenofovir; 3TC: lamivudine; NVP: nevirapine; LPV/r: lopinavir + ritonavir.
